5. Conclusions
obesity
OBESITY, METABOLIC SYNDROME
In this clinical trial, visceral fat was substantially reduced in the DW2010 group for 12 weeks, thus indicating the significance of DW2010 in visceral fat reduction. Moreover, visceral fat reduction could reduce the risk factors associated with obesity and metabolic syndrome. DW2010 is clinically safe and has therapeutic potential for treating obesity by regulating visceral fat. Subsequent studies are required to investigate the long-term visceral fat effects of DW2010 on human health.